ARQT - Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

2024-05-20 14:30:05 ET

Summary

• The use of Arcutis Biotherapeutics' Zoryve for plaque psoriasis patients was expanded to include patients between the ages of 6 and 11.
• Sales of Zoryve grew by 675% in Q1 2024 to $21.6 million.
• The FDA will decide on July 7th, 2024, whether Zoryve should be approved for the treatment of patients with atopic dermatitis, opening up another potential market opportunity.
• Zoryve was also approved for the treatment of patients with seborrheic dermatitis, opening the door to another patient population.

Arcutis Biotherapeutics Overview

The last time I spoke about Arcutis Biotherapeutics, Inc. ( ARQT ) it was gearing up to expand the label of its drug Zoryve [roflumilast] in several ways. I'm pleased to say that since then, it has attained most of this goal. Firstly, it had already received approval of this drug for the treatment of plaque psoriasis patients ages 12 and older, as stated in my prior article. The article was entitled " Arcutis Biotherapeutics: PDUFA Date Before End Of 2023 Makes This Worth A Look. " However, it was able to expand the label of Zoryve for the plaque psoriasis indication even further. This was with the ability to target younger patients, ages 6 to 11....

For further details see: